Research Topics
Genomes and GenesSpecies | Alexander JetterSummaryAffiliation: University of Cologne Country: Germany Publications
| Collaborators
|
Detail Information
Publications
Pharmacokinetics of piritramide in newborns, infants and young children in intensive care unitsCarsten Müller
University of Cologne, Department of Pharmacology, Medical Faculty of the University of Cologne, Gleuelerstr 24, 50931, Koln, Germany
Eur J Pediatr 165:229-39. 2006..Subsequent clinical trials for detailed dose adjustment of piritramide in paediatric patients comparing pharmacokinetics and effectiveness are needed...- Effects of grapefruit juice on the pharmacokinetics of sildenafilAlexander Jetter
Institute for Pharmacology, Clinical Pharmacology, University of Koln, Germany
Clin Pharmacol Ther 71:21-9. 2002..In this study we investigated the influence of grapefruit juice, containing inhibitors of intestinal CYP3A4, on the pharmacokinetics of sildenafil and N -desmethylsildenafil... - Phenotyping of N-acetyltransferase type 2 by caffeine from uncontrolled dietary exposureAlexander Jetter
Department of Pharmacology, Clinical Pharmacology, University of Cologne, Gleueler Strasse 24, 50931 Koln, Germany
Eur J Clin Pharmacol 60:17-21. 2004..We tested whether these standardization measures were still needed when a more sensitive quantification technique was used... - Cytochrome P450 2C9 phenotyping using low-dose tolbutamideAlexander Jetter
Department of Pharmacology, Clinical Pharmacology, University of Cologne, Gleueler Strasse 24, 50931 Cologne, Germany
Eur J Clin Pharmacol 60:165-71. 2004..However, therapeutically active doses of 500 mg bear the risk of hypoglycaemia, and a tolbutamide-derived parameter based on a single plasma or urine concentration reflecting CYP2C9 activity accurately is lacking... - Mesalazine pharmacokinetics and NAT2 phenotypeHendrik Lück
Department of Pharmacology, University Hospital, University of Cologne, Cologne, Germany
Eur J Clin Pharmacol 65:47-54. 2009..Mesalazine undergoes extensive metabolism by N-acetylation. While there is some evidence for an involvement of N-acetyltransferase (NAT) type 1, a potential role of NAT type 2 (NAT2) in vivo has not been tested... - In vivo role of cytochrome P450 2E1 and glutathione-S-transferase activity for acrylamide toxicokinetics in humansOxana Doroshyenko
Department of Pharmacology, University of Cologne, Cologne, Germany
Cancer Epidemiol Biomarkers Prev 18:433-43. 2009..No obvious genetic risks or protective factors in xenobiotic-metabolizing enzymes could be determined for exposed subjects... - Phenotyping of N-acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be collected?Alexander Jetter
Department of Pharmacology, Clinical Pharmacology, University Hospital Cologne, Koln, Germany
Eur J Clin Pharmacol 65:411-7. 2009..We investigated how ratios changed over time and which urine collection interval would be the best for NAT2 and XO activity assessments... - Assessment of urinary mephenytoin metrics to phenotype for CYP2C19 and CYP2B6 activityTobias Klaassen
Department of Pharmacology, Clinical Pharmacology, Hospital of the University of Cologne, Gleueler Str 24, 50931, Koln, Germany
Eur J Clin Pharmacol 64:387-98. 2008..We also assessed whether urinary excretion of N-desmethylmephenytoin (nirvanol) might be a useful CYP2B6 metric in in vivo studies... - Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimensChristoph Wyen
Department of Internal Medicine, University of Cologne, Cologne, Germany
J Antimicrob Chemother 66:2092-8. 2011.... - Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinideDorota Tomalik-Scharte
Department of Pharmacology, Clinical Pharmacology, University of Cologne, Gleueler Strasse 24, 50931 Koln, Germany
Drug Metab Dispos 39:927-32. 2011..In conclusion, CYP2C8*3 does not seem to play an important role in the pharmacokinetics and pharmacodynamics of repaglinide given in a therapeutic dose... - The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitroEugen Muschler
Department of Pharmacology, University of Cologne, Cologne, Germany
Basic Clin Pharmacol Toxicol 105:374-9. 2009..The evidence for substrate-specific inhibitory effects of pioglitazone on CYP2C-mediated metabolism needs to be tested in further studies... - The effect of silymarin on oral nifedipine pharmacokineticsUwe Fuhr
Department of Pharmacology, University Hospital, University of Cologne, Cologne, Germany
Planta Med 73:1429-35. 2007..Silymarin thus is not a potent CYP3A4 inhibitor IN VIVO... - Toxicokinetics of acrylamide in humans after ingestion of a defined dose in a test meal to improve risk assessment for acrylamide carcinogenicityUwe Fuhr
Department of Pharmacology, University Hospital, University of Cologne, Gleueler Strasse 24, 50931 Cologne, Germany
Cancer Epidemiol Biomarkers Prev 15:266-71. 2006..This should be considered for quantitative cancer risk assessment... - Assessment of CYP1A2 activity in clinical practice: why, how, and when?Mirko S Faber
Department of Pharmacology, Clinical Pharmacology, University of Cologne, , Germany
Basic Clin Pharmacol Toxicol 97:125-34. 2005..CYP1A2 phenotyping is applied frequently in epidemiologic and drug-drug interaction studies, but its clinical use and usefulness remains to be established... - Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patientsChristoph Wyen
Department of Internal Medicine, University of Cologne, Koln, Germany
J Antimicrob Chemother 61:914-8. 2008..The aim of this study was to investigate the frequency of CYP2B6 polymorphisms (according to ethnicity) and the influence of heterozygosity and homozygosity on plasma concentrations of efavirenz and nevirapine... - Clinical pharmacokinetics of trospium chlorideOxana Doroshyenko
Department of Pharmacology, Clinical Pharmacology Unit, University of Cologne, Cologne, Germany
Clin Pharmacokinet 44:701-20. 2005..The pharmacokinetics of the drug are compatible with twice-daily administration. A once-daily schedule may also be appropriate, but this regimen needs formal clinical evaluation... - Novel mutations of the extraneuronal monoamine transporter gene in children and adolescents with obsessive-compulsive disorderAndreas Lazar
Department of Pharmacology, University of Cologne, Cologne, Germany
Int J Neuropsychopharmacol 11:35-48. 2008..Heterologous expression of mutant cDNA revealed a 40% decline of transport capacity for norepinephrine. Rare mutations in the EMT gene suggest a causative or modulating role in genetic subtypes of OCD... - Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicityStefan Wilde
Department of Pharmacology, University Hospital, University of Cologne, Cologne, Germany
Clin Pharmacokinet 46:319-33. 2007..The present study was conducted to address the role of pharmacokinetics in individual toxicity... - How may anticancer chemotherapy with fluorouracil be individualised?Su-arpa Ploylearmsaeng
Department of Pharmacology, Clinical Pharmacology, University Hospital of Cologne, Cologne, Germany
Clin Pharmacokinet 45:567-92. 2006.... - Quantification of cyclophosphamide and its metabolites in urine using liquid chromatography/tandem mass spectrometryDirk Kasel
Department of Pharmacology, Clinical Pharmacology, University of Cologne, Gleueler Str. 24, 50931 Cologne, Germany
Rapid Commun Mass Spectrom 18:1472-8. 2004..5-27 microg/mL for 4KetoCP and 0.17-9 microg/mL for CarboxyCP and DCL-CP, respectively). The method was validated according to international guidelines of the ICH and the FDA... - Cytochrome P450 enzymes contributing to demethylation of maprotiline in manLars Brachtendorf
Institute for Pharmacology, Clinical Pharmacology, , Germany
Pharmacol Toxicol 90:144-9. 2002..Based on the parameters obtained, for plasma concentrations of 1 microM 83% (mean) of desmethylmaprotiline formation in vivo is expected to be mediated by CYP2D6 while 17% only may be attributed to CYPIA2 activity... - Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?Martina Kinzig-Schippers
Institute for Biomedical and Pharmaceutical Research, Paul Ehrlich Strasse 19, 90562 Nürnberg Heroldsberg, Germany
Antimicrob Agents Chemother 49:1733-8. 2005..Prospective clinical trials are required to assess the merits of this approach... - The CYP2C9 genotype does not influence sildenafil pharmacokinetics in healthy volunteersAlexander Jetter
Clin Pharmacol Ther 78:441-3. 2005 - Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotypeJulia Kirchheiner
Institute of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, Germany
Clin Pharmacol Ther 80:657-67. 2006..The purpose of this was to clarify the role of this polymorphism with regard to the pharmacokinetics and clinical effects of rosiglitazone...